Fingerprint
Dive into the research topics of '131I-tositumomab (Bexxar®) vs.90Y-ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed non-hodgkin lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
131I-tositumomab (Bexxar®) vs.90Y-ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed non-hodgkin lymphoma
Andrei Iagaru, Erik S. Mittra, Kristen Ganjoo, Susan J. Knox, Michael L. Goris
Research output: Contribution to journal › Article › peer-review
30
Scopus
citations